Posted on February 8, 2016 by Gray Connections
#LCSM Chat Topic 11-Feb: Online collaboration and support in the #LCSM community
Since June 2013, the #LCSM hashtag has been used by over 20,000 Twitter accounts, tweeted over 186,000 times, and generated over 541 million impressions. Participants include lung cancer patients, caregivers, family members, advocates, healthcare providers, hospitals, researchers, nonprofits, government agencies, journalists, pharma and the biotech industry. They use the hashtag to track new treatments, find patient resources, broadcast new research findings, develop advocacy activities, and connect with other lung cancer community members they might not find otherwise. #LCSM Co-Founder Janet Freeman-Daily will be presenting a research poster titled “Online Collaboration and Support… Read More
Posted on January 11, 2016 by Gray Connections
#LCSM Chat Topic 1/14: What Clinical Questions Can We Study to Improve Lung Cancer Treatment Outcomes?
Our topic for the next #LCSM Tweet Chat on Thursday, January 14th at 5 PM Pacific (8 PM Eastern) is “What Clinical Questions Can We Study to Improve Lung Cancer Treatment Outcomes?” In this chat, moderator Dr. David Tom Cooke (@DavidCookeMD) will facilitate brainstorming for clinical trial ideas. The chat is a continuation of #LCSM Chat’s ongoing Patient Centered Outcomes Research Institute (PCORI) funded project, entitled “Empowering Patients and Their Families to Improve Outcomes That Are Most Important to Them after Surgery and Other Therapies for Lung Cancer.” Patient-centered outcomes… Read More
Posted on December 14, 2015 by #LCSM Chat
#LCSM Chat Topic for 12/17: Reflecting on 2015, Projecting 2016 for the Lung Cancer Community
Some years are bigger than others, and by just about any measure, 2015 was a banner year for the lung cancer community. We saw new drug approvals for a wide range of lung cancer patients, including immunotherapy for patients with both squamous and non-squamous advanced NSCLC, as well as very recent approvals as holiday presents for patients with an EGFR mutation or ALK rearrangement. We saw many important trials in lung cancer become high priorities, a growing use of next generation sequencing to identify new targets, and new data and greater acceptance… Read More
#LCSM 
You must be logged in to post a comment.